Tovinotrine Shows No Benefit in Trials; Imara Will Stop Development
Imara is discontinuing the clinical development of tovinontrine (IMR-687), its experimental oral therapy for sickle cell disease (SCD) and beta-thalassemia, based on interim data from two Phase 2b clinical trials. While the therapy was generally safe and well tolerated in adults with both inherited blood disorders, it resulted in…